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proposal for recommendations that should 
provide the highest standard of care for 
older men with prostate cancer. The 
consensus of the SIOG Prostate Cancer Task 
Force is that older men with prostate cancer 
should be managed according to their 
individual health status, which is mainly 
driven by the severity of associated 
comorbid conditions, and not according to 
chronological age. Existing international 
recommendations (European Association of 
Urology, National Comprehensive Cancer 
Network, and American Urological 
Association) are the backbone for localized 
and advanced prostate cancer treatment, 
but need to be adapted to patient health 
status. Based on a rapid and simple 
evaluation, patients can be classiﬁed into 
four different groups: 1, ‘Healthy’ patients 
(controlled comorbidity, fully independent in 
daily living activities, no malnutrition) 
should receive the same treatment as 
younger patients; 2, ‘Vulnerable’ patients 
(reversible impairment) should receive 
standard treatment after medical 
intervention; 3, ‘Frail’ patients (irreversible 
impairment) should receive adapted 
treatment; 4, Patients who are ‘too sick’ with 
‘terminal illness’ should receive only 
symptomatic palliative treatment.
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elderly, guidelines, localized disease, 
metastatic, prostate cancer
Prostate cancer is the most prevalent cancer 
in men and predominantly affects older men 
(aged 
 
≥
 
70 years). The median age at 
diagnosis is 68 years; overall, two-thirds of 
prostate cancer-related deaths occur in men 
aged 
 
≥
 
75 years. With the exponential ageing 
of the population and the increasing life-
expectancy in developed countries, the 
burden of prostate cancer is expected to 
increase dramatically in the future. To date, 
no speciﬁc guidelines on the management 
of prostate cancer in older men have been 
published. The International Society of 
Geriatric Oncology (SIOG) conducted a 
systematic bibliographic search based on 
screening, diagnostic procedures and 
treatment options for localized and 
advanced prostate cancer, to develop a 
 
INTRODUCTION
 
Prostate cancer is the most frequently 
diagnosed male cancer in both the USA [1] 
and Europe [2]. It represents the second 
most common cause of cancer-related death 
in the USA [1] and the third cause in Europe 
[2]. Prostate cancer is predominantly a 
disease of older men (i.e. 
 
≥
 
70 years). 
According to the Surveillance, Epidemiology, 
and End Results database of the USA 
National Cancer Institute, the median age at 
diagnosis is 68 years and 71.2% of deaths 
due to prostate cancer occur in men aged 
 
≥
 
75 years [3]. With the exponential ageing 
of the population and the increasing life-
expectancy, especially in developed 
countries, the burden due to prostate cancer 
is expected to increase dramatically in the 
future.
Existing guidelines for the management of 
patients with prostate cancer [4–6] do not 
make speciﬁc treatment recommendations 
for older men. Although advanced age alone 
should not preclude effective treatment for 
prostate cancer, it is necessary to assess the 
risks and beneﬁts of treatment in each patient 
to avoid interventions that might decrease 
health-related quality of life (HRQL) without 
prolonging survival. Using a systematic review 
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of available literature, the International 
Society of Geriatric Oncology (SIOG) 
developed recommendations for the 
assessment and treatment of older men with 
prostate cancer. The full version of these 
recommendations was published recently [7]. 
The aim of this review is to provide the 
urologist with a short summary of evidence-
based recommendations, including speciﬁc 
decision algorithms, for managing older 
men with localized or advanced prostate 
cancer.
 
EVALUATION OF LIFE-EXPECTANCY AND 
HEALTH STATUS
 
Life-expectancy is a major determinant of the 
potential for beneﬁt from therapy beyond 
palliative care, yet it varies substantially 
between individuals within a given age group. 
Life-expectancy estimates apply to a 
population and represent a useful tool for 
public healthcare, but are not valid for a given 
individual. For example, 75-year-old men are 
expected to live for a further 8.3 years 
(median), but 
 
≈
 
25% (the upper quartile; likely 
to represent healthy individuals) will live for 
at least 14.2 years, whereas another 25% (the 
lower quartile; likely to represent frail 
individuals with signiﬁcant comorbid 
conditions) will live for 
 
<
 
4.9 years [8] (Fig. 1). 
Thus, although it is not possible to calculate 
the exact chance of survival for an individual, 
variables such as the number and severity of 
comorbidities and the extent of functional 
impairment can be used to predict the chance 
of surviving within an age group. Hence, 
it has been shown by Tewari 
 
et al
 
. [9] that 
comorbidity evaluated by the Charlson index 
was the strongest predictor of death from 
other than prostate cancer in men with 
localized prostate cancer treated with radical 
prostatectomy (RP). Age was also a signiﬁcant 
predictor of outcome, although to a lesser 
extent than comorbidity. It was also reported 
by Rockwood 
 
et al
 
. [10] that senior adult 
patients who are dependent in daily living 
activities have a shorter survival.
Health status inﬂuences patient survival and 
might affect the ability to tolerate treatment-
related side-effects. A previous SIOG Working 
Group concluded that screening for geriatric 
problems, using tools such as the 
Instrumental Activities of Daily Living (IADL), 
the Activities of Daily Living (ADL), the 
geriatric depression scale, and Folstein’s mini-
mental status, was not sufﬁcient for detecting 
age-related factors that would affect 
treatment outcomes in senior adults [11]. This 
screening stage should be followed by a more 
complete comprehensive geriatric assessment 
(CGA) which assesses various biological and 
clinical correlates of ageing on an individual 
basis, and includes diagnostic procedures, 
speciﬁc treatment plans, and geriatric 
intervention [7]. Several randomized 
controlled trials and meta-analyses have 
conﬁrmed the beneﬁt of CGA on survival, 
HRQL, institutionalization rates, and many 
other outcomes [11], and although few 
studies have speciﬁcally examined the beneﬁt 
of CGA in geriatric oncology, the available 
evidence generally supports the effectiveness 
of such an approach.
 
DEFINING PATIENT SUBGROUPS BY 
HEALTH STATUS
 
The SIOG Prostate Cancer Working Group 
reviewed recent literature and opinion on 
prognostic factors that might affect health 
status, overall survival, and prostate cancer-
speciﬁc survival [7]. The most important 
factors to consider for the evaluation of 
health status in older men with prostate 
cancer were comorbidities, dependence 
status, and nutritional status.
COMORBIDITIES
Comorbidity is a major predictor of non-
prostate cancer survival [9]. The Cumulative 
Illness Score Rating-Geriatrics (CISR-G) was 
judged to be the best available tool for 
assessing the risk for death unrelated to 
prostate cancer [12,13]. In contrast to the 
Charlson index, which considers only 
potentially lethal comorbid conditions, the 
CISR-G also rates nonlethal conditions 
according to their severity and level of control 
with treatment, as: Grade 0, no problem; 
Grade 1, current mild problem or past 
signiﬁcant problem; Grade 2, moderate 
disability or morbidity, requires ﬁrst-line 
therapy; Grade 3, severe/constant signiﬁcant 
disability/uncontrollable chronic problem; 
and Grade 4, extremely severe/immediate 
treatment required/end-organ failure/severe 
impairment in function.
DEPENDENCE STATUS
There is evidence that the level of dependence 
in daily living activities inﬂuences survival in 
senior adult patients [10]. Dependence can be 
easily evaluated using the ADL [14] and IADL 
[15] scales.
The ADL scale rates a patient’s ability to 
accomplish basic activities of daily living 
(bathing, dressing, toileting, transferring, 
continence, and feeding). One ADL 
impairment is considered abnormal in older 
men with prostate cancer, with the exception 
of incontinence.
The IADL scale rates activities that require a 
higher level of cognition and judgement. Four 
items apply to men with prostate cancer: 
ability to manage money, to manage 
medications, to use transportation, and to use 
the telephone. One IADL impairment is 
considered abnormal in older men with 
prostate cancer.
NUTRITIONAL STATUS
Malnutrition has also been shown to be 
associated with an increased mortality rate in 
senior adult patients [16]. Nutritional status 
can be estimated simply by the variation of 
weight during the previous 3 months: Good 
nutritional status, 
 
<
 
5% of weight loss; risk of 
malnutrition, weight loss 5-10%; severe 
malnutrition, weight loss 
 
>
 
10%.
 
EXPERT PANEL RECOMMENDATIONS
 
The SIOG Prostate Cancer Working Group 
recommends that the decision-making 
process for treating older men with prostate 
cancer should be based on a systematic 
evaluation of comorbidities (CISR-G scale), 
dependence status (IADL and ADL scales), and 
nutritional status (weight loss estimation). In 
cases of vulnerability and frailty, additional 
 
FIG. 1.
 
Life-expectancy in older men; there is a large 
variability reﬂecting variability in health status. 
Reprinted from [8], copyright (2001), with 
permission from the American Medical Association.
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geriatric interventions including a CGA might 
be needed.
These tools enable older men with prostate 
cancer to be classiﬁed into one of four health 
status categories [17]:
1
 
‘Healthy’ or ‘ﬁt’
 
: the patient has no serious 
comorbidity (CISR-G Grade 0, 1 or 2), is 
functionally independent (no dependence in 
IADL and ADL), and has no malnutrition. The 
health status of these patients is considered 
to be sufﬁcient to tolerate any form of 
standard cancer treatment.
2
 
‘Vulnerable’
 
: the patient is dependent in 
one or more IADL (but no dependence in ADL); 
or presents with one comorbid uncontrolled 
condition (CISR-G Grade 3); or is at risk of 
malnutrition (weight loss 5–10% within the 
last 3 months). Geriatric problems in this 
group should be reversible through geriatric 
intervention. These patients might beneﬁt 
from additional geriatric intervention, and 
they can receive standard cancer treatment 
after resolution of the geriatric problems.
3
 
‘Frail’
 
: the patient is dependent in one or 
more ADL; or presents with two or more 
uncontrolled comorbid conditions (i.e. at least 
two comorbidities CISR-G Grade 3 or one 
comorbidity CISR-G Grade 4); or has severe 
malnutrition (weight loss 
 
>
 
10% within the 
last 3 months). Patients in this group should 
beneﬁt from geriatric intervention and can be 
given speciﬁcally adapted cancer treatment.
4‘ T
 
oo sick’
 
: the patient has a very poor health 
status resulting from a combination of 
different impairments; likely to be suitable for 
palliative end-of-life treatment only.
These groups, rather than chronological age, 
should be used when considering treatment 
options for localized and advanced prostate 
cancer (Fig. 2A,B).
 
TREATMENT OF PROSTATE CANCER
 
The SIOG Prostate Cancer Working Group 
examined the standard approaches for 
managing and treating localized and 
advanced prostate cancer and applied, when 
possible, evidence-based considerations 
speciﬁc to the older population.
LOCALIZED PROSTATE CANCER
The aim of treatment for localized prostate 
cancer (T1–3, N0, M0 disease) is generally 
curative. Older men are more likely to develop 
larger tumours of a higher grade than are 
younger patients [18,19]. Nevertheless, there 
is evidence both from the USA [20] and 
Europe [21] that only a minority of patients 
will receive curative treatment. Decisions for 
treatment in older men with localized 
prostate cancer should take into 
consideration the risk of dying from prostate 
cancer (which depends of the grade and stage 
of the tumour), the risk of dying from another 
cause (which depends more on the severity of 
patient comorbidities than chronological age), 
potential adverse effects of treatment, and 
patient preferences.
In a retrospective analysis of 330 men with 
clinically localized prostate cancer diagnosed 
at age 70–74 years and managed by either 
surveillance or hormonal therapy for a 
median of 24 years, prostate cancer mortality 
 
FIG. 2.
 
A decision tree for treating patients with: 
 
A
 
, localized disease; and 
 
B
 
, metastatic disease.
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   impaired
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• Terminal
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rate was strongly related to the Gleason score, 
ranging from 22% for patients with a Gleason 
score of 
 
<
 
7 to 67% for those with a Gleason 
score of 
 
≥
 
8 (Fig. 3) [22].
Several risk-stratiﬁcation tools and 
nomograms have been developed to predict 
pathological stage and outcomes after 
various treatments. A commonly used tool is 
that developed by D’Amico 
 
et al
 
. [23] to 
evaluate the probability of biochemical 
relapse at 5 years after curative therapy. 
Patients are classiﬁed into three risk groups 
(low, medium, and high) based on biopsy 
Gleason score, preoperative PSA level and 
clinical stage. According to this classiﬁcation, 
there is evidence that older men at high risk of 
PSA relapse have a signiﬁcant probability of 
dying from prostate cancer compared with 
low- and intermediate-risk patients, and 
should therefore beneﬁt from curative 
treatment [24].
RP
The main recommendations for RP are 
summarized in Table 1; RP has been shown to 
improve life-expectancy in older patients with 
few comorbidities and moderately or poorly 
differentiated disease [25]. In patients with 
 
FIG. 3.
 
The causes of death in 330 men with 
clinically localized prostate cancer diagnosed 
when aged 70–74 years and managed by either 
surveillance or hormonal therapy for a median of 
24 years; from [22].
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TABLE 1 
 
A summary of the guidelines for RP and RT, highlighting references to age. Reprinted from [7], with permission from Elsevier
 
Guideline, year Guideline/recommendation
 
RP
 
AUA, 2007 update [6]
Based on the Expert Panel’s interpretation of the literature and opinion, the patient most likely to beneﬁt from RP would 
have a relatively long life-expectancy, no signiﬁcant surgical risk factors, and a preference for surgery
Candidates for surgery should have: (1) A life-expectancy longer than the expected morbidity of the cancer if left 
untreated; (2) No signiﬁcant surgical risk factors or serious comorbid conditions that would contraindicate an 
elective operation; (3) A willingness to undergo surgery after discussing the risks, operative side-effects, natural 
history, and options
EAU, 2008 update [4]
RP is a standard treatment in patients with stage T1b–T2b, Nx–N0, M0 disease, and a life-expectancy of 
 
>
 
10 years
RP is optional in younger patients with stage T1a disease and a long life-expectancy
RP is optional for selected patients with limited 
 
≤
 
T3a, Gleason score 
 
≤
 
8, PSA level of 
 
<
 
20 ng/mL, and long 
life-expectancy
NCCN 2009 [5]
RP is appropriate for any patient whose tumour is clinically conﬁned to the prostate, has a life-expectancy of 
 
≥
 
10 years 
and has no serious comorbid conditions that would contraindicate an elective operation
 
RT
 
AUA, 2007 update [6]
The patient most likely to beneﬁt from RT would have a relatively long life-expectancy, no signiﬁcant risk factors for 
radiation toxicity and a preference for RT
Comment: Insufﬁcient follow-up to compare survival outcomes of EBRT and brachytherapy
NCCN 2009 [5]
Treatment recommendations are based on anticipated life-expectancies and risk of recurrence:
1 Low risk of recurrence (stage T1–T2a, low Gleason score 2–6, and PSA level 
 
<
 
10 ng/mL: RT (3-D EBRT or
brachytherapy) is an acceptable strategy in patients whose age or comorbidity leads to a life-expectancy of 
 
<
 
10 years
and in patients with a life-expectancy of 
 
≥
 
10 years
2 Intermediate risk of recurrence (stage T2b–T2c, Gleason score 7, or PSA level 10–20 ng/mL): RT (EBRT with or
without brachytherapy) is a treatment option in men with a life-expectancy of 
 
<
 
10 or 
 
≥
 
10 years
EAU, 2008 update [4]
Treatment decision should be based on TNM classiﬁcation, Gleason score, baseline PSA level, age, comorbidity, 
life-expectancy, and HRQL:
1 3D-CRT with or without IMRT is recommended for patients with T1c–T2c N0 
 
M
 
0 disease. There is fairly strong
evidence that intermediate-risk patients (T2b, PSA 10–20 ng/mL, or Gleason score of 7) beneﬁt from dose escalation.
2 Transperineal interstitial brachytherapy without permanent implants can be proposed for patients with cT1–T2a–b,
Gleason score 
 
<
 
7 (or 3 
 
+
 
 4), PSA 
 
≤
 
10 ng/mL, prostate volume 
 
≤
 
60 mL, without previous TURP, and with a good
IPSS
 
3D-CRT, three-dimensional conformal RT; IMRT, intensity-modulated RT. 
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severe comorbidities, the risk of death from 
prostate cancer should be carefully balanced 
with the risk of dying from another cause. 
The risk of short-term postoperative 
complications also appears to be more related 
to the severity of comorbidities than 
chronological age [26]. Conversely, the risk 
of long-term incontinence, a common 
complication after RP, seems markedly 
more inﬂuenced by increasing age than 
comorbidity [26].
EXTERNAL BEAM RADIOTHERAPY (EBRT)
The main recommendations in prostate 
cancer guidelines for EBRT are also 
summarized in Table 1. Studies have shown 
similar outcomes in terms of cancer control 
and treatment-related comorbidities in both 
older and younger patients. The combination 
of RT with adjuvant androgen-deprivation 
therapy (ADT) has been shown to improve the 
5- and 8-year survival rates in patients with 
stage T3/T4 disease, whereas there was no 
survival advantage for men with T1/T2 disease 
[27]. However, a recent report by D’Amico 
 
et al
 
. [28] suggests that this survival beneﬁt 
might only apply to high-risk patients with no 
or minimal comorbidities.
BRACHYTHERAPY
Brachytherapy is indicated in patients with 
low-risk prostate cancer, a prostate volume of 
 
<
 
50 cm
 
3
 
, and a good IPSS [4]. Brachytherapy 
might be a suitable option in older patients, 
but the survival beneﬁt in older men with 
low-risk disease has not yet been established. 
Although complications are generally less 
severe than with RP, urinary, bowel and 
erectile complications increase signiﬁcantly 
with both increasing age and severity of 
comorbidities [4].
ADT
In patients with nonmetastatic prostate 
cancer unsuitable for curative treatment, 
immediate ADT had a modest beneﬁt on overall 
survival, but had no effect on prostate cancer 
mortality and symptom-free survival rates, 
except possibly in patients with a PSA level of 
 
>
 
50 ng/mL and a PSA doubling time of 
 
<
 
12 
months [29,30]. However, ADT can be used for 
patients who need symptom palliation and 
who are unﬁt for curative therapy.
Besides the lack of compelling evidence for 
the use of ADT in localized prostate cancer, 
care is particularly needed in older men, 
as ADT is associated with an increased 
risk of fractures [31], diabetes [32] and 
cardiovascular morbidity [33]. Older men with 
a low baseline bone mineral density or a high 
rate of bone loss during hormone therapy 
could be considered candidates for 
bisphosphonate therapy.
‘WATCH-AND-WAIT’ POLICY AND 
ACTIVE SURVEILLANCE
Patients likely to beneﬁt from a ‘watch-and-
wait’ policy (i.e. expectant management) or 
‘active surveillance’ (involving delayed 
intervention on progression) are those in the 
low-risk group as deﬁned by D’Amico 
 
et al
 
. 
[24], those who have a short life-expectancy 
(advanced age, severe comorbidities), and 
those who express a personal preference to 
avoid or delay the side-effects of deﬁnitive 
therapy.
For patients in the intermediate-risk group, 
the risk of dying from prostate cancer should 
be carefully balanced with the risk of dying 
from another cause. This group of patients 
would deserve further evaluation, especially 
considering that the likelihood of being 
upstaged from clinical T1–T2 to pathological 
T3–T4, or upgraded from a biopsy Gleason 
score of 
 
<
 
7 to a pathological Gleason score of 
7–10 is higher in men aged 
 
≥
 
70 years than in 
younger patients [18].
In summary, the decision making is based on 
the evaluation of the competition between 
the risk of dying from prostate cancer and the 
risk of dying from health status impairment. 
One approach of both aspects, health status 
being limited to comorbidities evaluated by 
the Charlson Index, is the practical use of a 
speciﬁc nomogram [34]. Another approach is 
a combination of a simpliﬁed evaluation of 
health status and a simple evaluation of risk 
factors for prostate cancer that we have 
introduced in these recommendations. 
However, even the choice of a risk factor 
classiﬁcation for prostate cancer can be 
discussed; it was shown that in classiﬁcation 
of D’Amico 
 
et al
 
., the intermediate- and high-
risk groups overlapped when using a 
nomogram-based risk group assessment in 
patients who were treated by RP [35]. This in 
favour of considering both risk groups for 
active treatment even in vulnerable patients. 
We have chosen the D’Amico 
 
et al
 
. 
classiﬁcation because it is widely used for RT, 
which is the most frequently used curative 
treatment in older men.
 
EXPERT PANEL RECOMMENDATIONS FOR 
LOCALIZED PROSTATE CANCER
 
Treatment decisions should be based on a 
health status evaluation (mainly driven by the 
severity of associated comorbidities) rather 
than chronological age, and on patient 
preference.
‘Fit’ and ‘vulnerable’ older men in the high-risk 
group deﬁned by D’Amico 
 
et al
 
. [23], with a 
chance of surviving for 
 
>
 
10 years are likely to 
beneﬁt from curative treatment.
Older men in the ‘low-risk’ and possibly in 
the ‘intermediate-risk’ groups of the risk 
classiﬁcation [23] are likely to beneﬁt from an 
active surveillance approach.
The beneﬁts and harms of ADT for localized 
prostate cancer should be carefully balanced 
in older men. Attention is drawn to an 
increased risk of diabetes, cardiovascular 
complications, and osteoporosis and bone 
fractures.
 
ADVANCED PROSTATE CANCER
 
ADT is the mainstay of treatment for patients 
with metastatic prostate cancer. Surgical 
castration and castration by LHRH agonists 
are the standard of care for ﬁrst-line 
treatment. There is no established difference 
in efﬁcacy between these treatments; 
however, the use of LHRH agonists is usually 
preferred because it avoids the physical and 
psychological discomfort of bilateral 
orchidectomy [4].
The standard procedure for second-line 
hormonal treatment is cessation of 
antiandrogen if given as ﬁrst-line treatment 
in association with an LHRH agonist. 
Importantly, there is currently no established 
survival beneﬁt with second-line and 
subsequent lines of hormone therapy. When 
prostate cancer becomes castration-
refractory it is recommended that LHRH 
agonist therapy is continued, but there are no 
available data speciﬁcally supporting this 
approach in older men.
Given the increased risk of osteoporosis and 
fracture in older men on ADT, care is needed  
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[5]. All men receiving ADT should receive 
calcium and vitamin D supplementation, 
and baseline bone mineral density should 
be determined. The routine use of 
bisphosphonates to prevent skeletal 
complications in patients undergoing ADT 
is not recommended unless there is a 
documented risk for fracture or castration-
resistant prostate cancer (CRPC) with skeletal 
metastases.
CHEMOTHERAPY IN CRPC
There is growing acceptance that older 
age, 
 
per se
 
, is not a contraindication to 
chemotherapy in older men and that many 
older patients tolerate it as well as younger 
patients [5]. Docetaxel-based regimens are 
the standard of care for patients with CRPC 
because they provide a survival advantage 
while reducing pain and improving HRQL 
[36–38]. In a subgroup analysis, the survival 
beneﬁt of 3-weekly docetaxel compared with 
mitoxantrone was consistent between age 
groups, with hazard ratios for overall survival 
in patients aged 
 
≤
 
68 and 
 
>
 
68 years of 0.81 
and 0.77, respectively [36]. Using a more 
extreme age threshold of 
 
>
 
75 years, the 
hazard ratio was 0.80.
In a retrospective analysis of 175 patients 
aged 
 
≥
 
75 years treated with docetaxel (either 
a 3-weekly or a weekly regimen, according to 
clinical judgement), patients with a good 
performance status responded to docetaxel 
therapy to a similar extent as younger 
patients. Docetaxel was generally well 
tolerated; the weekly regimen showed less 
febrile neutropenia than the 3-weekly 
regimen but a higher rate of fatigue, resulting 
in frequent treatment discontinuation [39]. In 
real-life practice, healthy or vulnerable older 
patients usually receive the 3-weekly regimen, 
whereas frail patients are more likely to 
receive the weekly regimen [40].
To date, there is no evidence to support 
primary prophylaxis with granulocyte 
colony-stimulating factor in this setting; 
nevertheless, this agent can be given in 
selected cases, based on the speciﬁc risk of 
toxicity.
RT/RADIOPHARMACEUTICALS
RT is the ﬁrst choice for localized painful 
metastasis and is useful in the treatment of 
painful lesions in older patients with CRPC. As 
yet, no study has been conducted speciﬁcally 
in older men, but the toxicity proﬁle of 
radiopharmaceuticals appears appropriate for 
administration in these patients.
 
EXPERT PANEL RECOMMENDATIONS FOR 
ADVANCED PROSTATE CANCER
 
• ADT is the ﬁrst-line treatment in hormone-
sensitive metastatic prostate cancer. 
Evaluation of bone mineral status and 
prevention of osteoporosis are recommended.
• In metastatic CRPC, chemotherapy with 
docetaxel (75 mg/m
 
2
 
 every 3 weeks) is the 
standard for ﬁt and vulnerable older men.
• The tolerability of the docetaxel 3-weekly 
regimen has not been speciﬁcally studied in 
frail older men. The place of weekly docetaxel 
in metastatic CRPC should be further 
evaluated.
• Palliative treatments include palliative 
surgery, radiopharmaceuticals, RT and 
medical treatments for pain and symptoms.
 
PROSTATE CANCER SCREENING
 
Screening in older men with prostate cancer is 
highly controversial. Individualized screening 
decisions should be based on patient health 
status but not on chronological age.
 
SUMMARY
 
Prostate cancer is a disease of older men; the 
median age at diagnosis is 68 years, and 75% 
of deaths due to prostate cancer occur in men 
aged 
 
≥
 
75 years. There is also evidence that 
older men are more likely to develop larger 
tumours of a higher grade than are younger 
patients. With the exponential ageing of the 
population and the increasing life-expectancy 
in developed countries, the burden of prostate 
cancer is expected to increase dramatically.
The SIOG Prostate Cancer Working Group has 
developed evidence-based recommendations 
for the management of older men with 
prostate cancer which can be summarized as 
follows:
• The urological approach in older men with 
prostate cancer should be the same as in 
younger patients, based on existing 
international recommendations [4–6].
• Older men with prostate cancer should be 
managed according to their individual health 
status, which is mainly driven by the severity 
of associated comorbid conditions, 
dependence and nutritional status and not 
according to chronological age.
• Screening for health status should include 
evaluation of comorbid conditions (CISR-G 
scale), dependence status (IADL and ADL 
scales), and nutritional status (weight loss 
estimation). In cases of vulnerability and 
frailty, additional geriatric interventions, 
including a CGA, might be needed. This allows 
patients to be easily and rapidly classiﬁed into 
one of four groups:
1 ‘Fit’ or ‘healthy’ older men should receive 
the same standard treatment as younger 
patients. More speciﬁcally, they should receive 
curative therapy in cases of high-risk localized 
prostate cancer and standard chemotherapy 
in cases of CRPC.
2 ‘Vulnerable’ patients (i.e. reversible 
impairment) should receive standard 
treatment after resolution of any geriatric 
problems through geriatric interventions.
3 ‘Frail’ patients (i.e. irreversible impairment) 
should receive an adapted treatment.
4  Patients who are ‘too sick’ with ‘terminal 
illness’ should receive only symptomatic 
palliative treatment.
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